Singapore
Industry
BMI View: German drugmaker Bayer is unlikely to repeat its so-far impressive performance in Asia Pacific in the remainder of 2011, primarily due to the region's stagnating attractiveness...
2011-07-07Industry
BMI View: Attention deficit hyperactivity disorder (ADHD) represents a small but growing opportunity for pharmaceutical companies operating in South East Asia. The prevalence of the...
2011-05-04Industry
BMI View: High standards of medical care and knowledge will work towards boosting growth in Singapore's medical tourism sector. A recent government survey revealed that 76% of the patients...
2011-04-18Industry
BMI Core View: Non-healthcare companies, particularly technology firms, will increasingly enter the medical services sector. Companies see healthcare as a sustainable and expanding...
2011-04-14Industry
BMI View: Singapore's healthcare sector is small, but will post steady growth over the next decade. The key drivers of this expansion are a growing economy, an ageing population, more...
2011-02-15Industry
BMI View: Singapore has a low risk pharmaceutical market. Despite having an economy that is highly dependent on exports (demand for which is inherently volatile), the country is committed...
2011-02-10Industry
BMI View: Asia Pacific's attractiveness to multinational drugmakers is faltering. BMI's Pharmaceuticals & Healthcare Business Environment Ratings (BERs), which assess countries...
2011-01-14Industry
BMI Core View: Non-healthcare companies, particularly technology firms, will increasingly enter the medical services sector. Companies see healthcare as a sustainable and expanding...
2010-11-25




